Ironwood Pharmaceuticals, Inc. logo IRWD - Ironwood Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 11
HOLD 16
SELL 3
STRONG
SELL 0
| PRICE TARGET: $6.68 DETAILS
HIGH: $18.00
LOW: $1.00
MEDIAN: $5.00
CONSENSUS: $6.68
UPSIDE: 63.73%

Stock News

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood.

Sep 03, 2026 12:05 PM • businesswire.com
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance. “Throughout the first half of the year, we have remained laser focused on meaningful execution of our three strategic priorities: maximizing LINZESS, advancing apraglutide, and delivering sustained profit.

Aug 06, 2026 03:05 AM • businesswire.com
Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth

Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth

Despite the recent market selloff, earnings expectations continue to rise: The S&P 500's Q2 EPS is projected to grow by 37.9%, while net profit margins could reach a 15-year high. Buying the dip can present opportunities for investors. When fear fades, markets have historically returned to fundamentals. Using Seeking Alpha's Quant Tools, I found two Strong Buy stocks, beaten down in the past month, offering both solid growth and value.

Jul 31, 2026 05:00 AM • seekingalpha.com
Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust

Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust

Ironwood Pharmaceuticals trades at a 40% discount to its risk-adjusted sum-of-the-parts valuation, anchored by LINZESS and apraglutide. I assign a 'Buy' rating on IRWD and a $6.3 price target, citing a margin of safety, but I also warn of a binary risk tied to apraglutide's pivotal trial. LINZESS faces a patent cliff in 2029, with revenue projected to decay rapidly following the entry of generic products.

Jul 30, 2026 05:43 AM • seekingalpha.com
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his successor. Dr. Silber will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs reporting.

Jul 14, 2026 03:30 AM • businesswire.com
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceutic.

May 28, 2026 12:05 PM • businesswire.com
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.

May 27, 2026 06:00 AM • businesswire.com

Price Targets